ARCHIVES

ODAC Member Critical Of Amgen For Price Incentives.

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | March 21, 2008

Download PDF Visit The Full Archive

Related Articles

DCPC Board approves New CCOP RFA Following Addition Of Public Health, Education Components

May 16, 1986

RFA On Pathology Training Released

February 1, 1980

In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs

January 17, 1992

Project Expands Group Studies To Community Oncologists.

March 10, 2000

“Mini-Transplantation” In Testing For Treatment Of Multiple Myeloma

January 25, 2002

32% Rise In Breast Cancer Diagnosis In 1980s Explained By Increase In Mammography Screening

September 21, 1990